Laurence Albigès, MD, PhD, on Key Findings From CheckMate 214 of Nivolumab Plus Ipilimumab in Advanced RCC

Laurence Albigès, MD, PhD, shares updated key findings from the phase 3 CheckMate 214 trial.

During the 2022 Genitourinary Cancers Symposium, CancerNetwork® spoke with Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, about her key takeaways from the 5-year updated analysis from phase 3 CheckMate 214 trial (NCT02231749), assessing the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) in treatment-naïve advanced or metastatic renal cell carcinoma.1

Findings from the study highlighted an overall survival (OS) benefit with the combination regimen vs sunitinib (Sutent). Importantly, the benefit appeared to be sustained over time, according to Albigès.


CheckMate 214 was first reported in 2018.2 The key message is that for the first time, we have challenged the use of a single-agent VEGF targeting strategy, namely sunitinib, as the comparator arm with a combination of 2 immune checkpoint inhibitors, nivolumab plus ipilimumab. We do know that in RCC, VEGF targeting is very important. This trial was very innovative because it [examined] having a strong and potent immune checkpoint inhibitor combination as a frontline strategy.

The key finding is that this trial demonstrated an [OS] benefit in favor of nivolumab plus ipilimumab. This benefit in terms of OS has been reported with a minimum follow up of 17 months, but [longer follow-up shows this has been] sustained over time. We had 30 months of follow up, 42 months of follow up, [and] now 60 months of follow up with a very consistent hazard ratio [for OS] of 0.68, clearly favoring the doublet immune checkpoint regimen over single-agent sunitinib.


  1. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352
  2. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126